Yoshida K, Zhao P, Zhang L, Abernethy DR, Rekic D, Reynolds KS, et al. In vitro-in vivo extrapolation of metabolism- and transporter-mediated drug-drug interactions: overview of basic prediction methods. J Pharm Sci. 2017;106(9):2209–13.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. In vitro drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for industry. January 2020:1-46. Available from: https://www.fda.gov/media/134582/download. Accessed 25 May 2024.

Saad AAA, Zhang F, Mohammed EAH, Wu X. Clinical aspects of drug-drug interaction and drug nephrotoxicity at renal organic cation transporters 2 (OCT2) and multidrug and toxin exclusion 1, and 2-K (MATE1/MATE2-K). Biol Pharm Bull. 2022;45(4):382–93.

Article  CAS  PubMed  Google Scholar 

Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, International Transporter Consortium, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.

Article  PubMed  Google Scholar 

Zhang L, Liu Q, Huang SM, Lionberger R. Transporters in regulatory science: notable contributions from Dr. Giacomini in the past two decades. Drug Metab Dispos. 2022;50(9):1211–7.

Article  PubMed  PubMed Central  Google Scholar 

Burt HJ, Neuhoff S, Almond L, Gaohua L, Harwood MD, Jamei M, et al. Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. Eur J Pharm Sci. 2016;88:70–82.

Article  CAS  PubMed  Google Scholar 

Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(11):820–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, et al. Elucidation of N (1)-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters. Drug Metab Dispos. 2019;47(11):1270–80.

Article  CAS  PubMed  Google Scholar 

Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825–92.

Article  CAS  PubMed  Google Scholar 

Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol. 2012;8(4):433–48.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. ICH guideline M12 on drug interaction studies, Step 2b (draft), July 21, 2022. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf. Accessed 25 May 2024.

Motohashi H, Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013;15(2):581–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gessner A, Konig J, Fromm MF. Clinical aspects of transporter-mediated drug-drug interactions. Clin Pharmacol Ther. 2019;105(6):1386–94.

Article  CAS  PubMed  Google Scholar 

Maideen NMP, Jumale A, Balasubramaniam R. Drug interactions of metformin involving drug transporter proteins. Adv Pharm Bull. 2017;7(4):501–5.

Article  CAS  Google Scholar 

Feng B, Varma MV. Evaluation and quantitative prediction of renal transporter-mediated drug-drug interactions. J Clin Pharmacol. 2016;56(Suppl. 7):S110–21.

CAS  PubMed  Google Scholar 

Pfizer. Methotrexate tablets, for oral use. Prescribing information, revised: 08/2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/040054s015,s016,s017.pdf. Accessed 8 Aug 2023.

Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, et al. Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects. J Pharmacol Exp Ther. 2019;368(1):136–45.

Article  CAS  PubMed  Google Scholar 

Iwaki M, Shimada H, Irino Y, Take M, Egashira S. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull. 2017;40(6):926–31.

Article  CAS  PubMed  Google Scholar 

Pfizer. Furosemide injection (furosemide), for intravenous or intramuscular use. Prescribing information, revised: 2/2023. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=4630. Accessed 10 Sep 2023.

Łapczuk-Romańska J, Droździk M, Oswald S, Droździk M. Kidney drug transporters in pharmacotherapy. Int J Mol Sci. 2023;24(3):2856.

Article  PubMed  PubMed Central  Google Scholar 

Miyake T, Kimoto E, Luo L, Mathialagan S, Horlbogen LM, Ramanathan R, et al. Identification of appropriate endogenous biomarker for risk assessment of multidrug and toxin extrusion protein-mediated drug-drug interactions in healthy volunteers. Clin Pharmacol Ther. 2021;109(2):507–16.

Article  CAS  PubMed  Google Scholar 

Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, et al. Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the International Transporter Consortium. Clin Pharmacol Ther. 2018;104(5):836–64.

Article  CAS  PubMed  Google Scholar 

Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 2019;105(6):1345–61.

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Guidance on the investigation of drug interactions. Revision 1, 2015. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 13 Jun 2023.

Arya V, Reynolds KS, Yang X. Using endogenous biomarkers to derisk assessment of transporter-mediated drug-drug interactions: a scientific perspective. J Clin Pharmacol. 2022;62(12):1501–6.

Article  CAS  PubMed  Google Scholar 

Mathialagan S, Feng B, Rodrigues AD, Varma MVS. Drug-drug interactions involving renal OCT2/MATE transporters: clinical risk assessment may require endogenous biomarker-informed approach. Clin Pharmacol Ther. 2021;110(4):855–9.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for industry. January 2020:1-27. Available from: https://www.fda.gov/media/134581/download. Accessed 25 May 2024.

Dong Z, Yang X, Arya V, Zhang L. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity (NME) to inhibit organic anion transporter 1 and 3 (OAT1 and OAT3) in vivo (abstract PII-075). Clin Pharmacol Ther. 2016;99:S94–5.

Google Scholar 

Willemin ME, Van Der Made TK, Pijpers I, Dillen L, Kunze A, Jonkers S, et al. Clinical investigation on endogenous biomarkers to predict strong OAT-mediated drug-drug interactions. Clin Pharmacokinet. 2021;60(9):1187–99.

Article  CAS  PubMed  Google Scholar 

Gessner A, Müller F, Wenisch P, Heinrich MR, König J, Stopfer P, et al. A metabolomic analysis of sensitivity and specificity of 23 previously proposed biomarkers for renal transporter-mediated drug-drug interactions. Clin Pharmacol Ther. 2023;114(5):1058–72.

Article  CAS  PubMed  Google Scholar 

Müller F, Sharma A, Konig J, Fromm MF. Biomarkers for in vivo assessment of transporter function. Pharmacol Rev. 2018;70(2):246–77.

Article  PubMed  Google Scholar 

Rodrigues AD, Taskar KS, Kusuhara H, Sugiyama Y. Endogenous probes for drug transporters: balancing vision with reality. Clin Pharmacol Ther. 2018;103(3):434–48.

Article  CAS  PubMed  Google Scholar 

Li Y, Talebi Z, Chen X, Sparreboom A, Hu S. Endogenous biomarkers for SLC transporter-mediated drug-drug interaction evaluation. Molecules. 2021;26(18):5500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Türk D, Müller F, Fromm MF, Selzer D, Dallmann R, Lehr T. Renal transporter-mediated drug-biomarker interactions of the endogenous substrates creatinine and N(1)-methylnicotinamide: a PBPK modeling approach. Clin Pharmacol Ther. 2022;112(3):687–98.

Article  PubMed  Google Scholar 

Mathialagan S, Rodrigues AD, Feng B. Evaluation of renal transporter inhibition using creatinine as a substrate in vitro to assess the clinical risk of elevated serum creatinine. J Pharm Sci. 2017;106(9):2535–41.

Article  CAS